A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target - Inserm - Institut national de la santé et de la recherche médicale
Article Dans Une Revue Nature Communications Année : 2018

A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

Résumé

The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning ("Causal Reasoning Analytical Framework for Target discovery"-CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for identifying cell membrane receptors with a direction-specified influence over disease-related gene expression profiles. As proof of concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy seizures was validated in three pre-clinical models of epilepsy. These results highlight CRAFT as a systems-level framework for target discovery and suggest Csf1R blockade as a novel therapeutic strategy in epilepsy. CRAFT is applicable to disease settings other than epilepsy.
Fichier principal
Vignette du fichier
s41467-018-06008-4.pdf (1.37 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

inserm-04713631 , version 1 (29-09-2024)

Licence

Identifiants

Citer

Prashant K Srivastava, Jonathan van Eyll, Patrice Godard, Manuela Mazzuferi, Andree Delahaye-Duriez, et al.. A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. Nature Communications, 2018, 9 (1), pp.3561. ⟨10.1038/s41467-018-06008-4⟩. ⟨inserm-04713631⟩

Collections

INSERM IMRB UPEC
13 Consultations
5 Téléchargements

Altmetric

Partager

More